May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Soluble Neuropilin-1 Inhibits Retinal Neovascularization (NV)
Author Affiliations & Notes
  • J. Shen
    Ophthalmology, Wilmer Eye Institute, Baltimore, MD, United States
  • J. Zimmer
    Ophthalmology, Wilmer Eye Institute, Baltimore, MD, United States
  • Y. Oshima
    Ophthalmology, Wilmer Eye Institute, Baltimore, MD, United States
  • D. Leahy
    Biophysics, The Johns Hopkins University School of Medicine, Baltimore, MD, United States
  • P. Campochiaro
    Biophysics, The Johns Hopkins University School of Medicine, Baltimore, MD, United States
  • Footnotes
    Commercial Relationships  J. Shen, None; J. Zimmer, None; Y. Oshima, None; D. Leahy, None; P. Campochiaro, None.
  • Footnotes
    Support  EY05951, EY12069
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 576. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Shen, J. Zimmer, Y. Oshima, D. Leahy, P. Campochiaro; Soluble Neuropilin-1 Inhibits Retinal Neovascularization (NV) . Invest. Ophthalmol. Vis. Sci. 2003;44(13):576.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Neuropilin-1 (Npn1) is a coreceptor for vascular endothelial growth factor 165 isoform (VEGF165), which enhances VEGF165 binding to high affinity VEGF receptor 2, and plays an important role in regulation of the mitogenic and chemotactic activity of VEGF. Npn1 plays an important role in vascular development. The aim of this study was to determine whether intraocular injection of a portion of the extracellular domain containing the B1 VEGF binding site, soluble Npn1 (sNpn1), inhibits retinal neovascularization in mice with oxygen-induced ischemic retinopathy. Methods: A protein encompassing the a1, a2, b1, and b2 domains of rat Npn1 was expressed in CHO cells and purified from conditioned medium. Litters of C57BL/6 mice were placed in 75% oxygen at postnatal day P7. At P12, they were removed from oxygen and given an intravitreous injection of 400ng or 800ng of sNpn1 in one eye and in the contralateral eye, they received an injection of 800ng of BSA. At P17, mice were sacrificed and retinal NV was measured by image analysis. At various time points in mice with ischemic retinopathy that were not injected with sNpn1, Npn1 mRNA levels in the retina were assessed by RT-PCR and Npn1 expression was localized by immunohistochemistry. Results: In mice with ischemic retinopathy, increased levels of Npn1 mRNA were present in the retina from P13 to p17. Staining for Npn1 was localized to retinal NV. Compared to intravitreous injection of BSA at P12 (0.1994±0.0708, n=8,), intravitreous injection of 400ng (0.0734±0.0299, n=12, p=0.0027) or 800ng (0.1366±0.0159, n=8, p=0.031) of sNpn1 resulted in significantly less retinal NV at P17. Conclusions: There is increased expression of Npn1 in neovascular tissue in the retina. Intravitreous injection of sNpn1 suppresses the development of retinal NV in mice with ischemic retinopathy. Signaling through Npn1 may contribute to retinal NV in ischemic retinopathy and sNpn1suppresses retinal NV, probably by sequestering VEGF.

Keywords: retinal neovascularization • animal model • receptors: pharmacology/physiology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×